

UNAUDITED FINANCIAL RESULTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2008

AVENTIS PHARMA LIMITED

Registered Office : Aventis House, 54/A, Sir Mathuradas Vasanji Road,
Andheri East, Mumbai 400 093

(Rs. Million)

Particulars	Quarter ended 30.09.2008 (Unaudited)	Quarter ended 30.09.2007 (Unaudited)	Nine Months ended 30.9.2008 (Unaudited)	Nine Months ended 30.9.2007 (Unaudited)	Year ended 31.12.2007 (Audited)
1 (a) Net Sales	2,479	2,264	7,134	6,695	8,735
(b) Other Operating Income	137	106	367	318	428
Total	2,616	2,370	7,501	7,013	9,163
2 Expenditure					
a) Increase /decrease in stock in trade and work in progress	(96)	2	33	(59)	(87)
b) Consumption of raw materials	835	686	2,141	2,169	2,772
c) Purchase of traded goods	479	433	1,252	1,196	1,635
d) Employees Cost	291	247	868	737	1,037
e) Depreciation	43	47	138	139	185

Particulars	Quarter ended 30.09.2008 (Unaudited)	Quarter ended 30.09.2007 (Unaudited)	Nine Months ended 30.9.2008 (Unaudited)	Nine Months ended 30.9.2007 (Unaudited)	Year ended 31.12.2007 (Audited)
f) Other expenditure	491	450	1,451	1,267	1,703
g) Total	2,043	1,865	5,883	5,449	7,245
3 Profit from Operations before Other Income and Interest (1-2)	573	505	1,618	1,564	1,918
4 Other Income	116	70	271	240	312
5 Profit before Interest (3+4)	689	575	1,889	1,804	2,230
6 Interest	-	2	1	2	2
7 Profit before tax (5-6)	689	573	1,888	1,802	2,228
8 Tax Expense	243	205	679	628	784
9 Net Profit for the Period (7-8)	446	368	1,209	1,174	1,444
10 Paid-up equity share capital Face Value of Rs.10 per Share)	230	230	230	230	230
11 Reserves excluding Revaluation Reserves as per	-	-	-	-	6,651

Particulars	Quarter ended 30.09.2008 (Unaudited)	Quarter ended 30.09.2007 (Unaudited)	Nine Months ended 30.9.2008 (Unaudited)	Nine Months ended 30.9.2007 (Unaudited)	Year ended 31.12.2007 (Audited)
balance sheet of previous accounting year					
12 Earnings Per Share (EPS)(Rs)(Basic and diluted EPS for the period for the year to date and for the previous year	19.39	16.00	52.56	51.04	62.71
13 Public Shareholding					
- Number of Shares	9,120,955	9,120,955	9,120,955	9,120,955	9,120 955
- Percentage of Shareholding	39.60	39.60	39.60	39.60	39.60

Notes:

- The above Results were approved by the Board of Directors of the Company at its Meeting held on July 24, 2008.
- The break up of Net Sales is as follows:

(Rs Million)

	Quarter ended Sept. 30, 2008	Quarter ended Sept. 30, 2007	Growth %	Nine months ended Sept. 30, 2008	Nine months ended Sept. 30, 2007	Growth %
Domestic Sales	1,957	1,783	9.8%	5,720	5,322	7.5%

	Quarter ended Sept. 30, 2008	Quarter ended Sept. 30, 2007	Growth %	Nine months ended Sept. 30, 2008	Nine months ended Sept. 30, 2007	Growth %
Export Sales	522	481	8.6%	1,414	1,373	3.0%
Total Sales	2,479	2,264	9.5%	7,134	6,695	6.6%

- The company has a single business segment namely "Pharmaceutical Business".
- With regard to the Arbitration proceedings in the dispute with Chiron Behring Vaccines Private Limited and Novartis Vaccines & Diagnostics Inc., USA on the notice of non-renewal of distribution rights for Rabipur Vaccine for India and Nepal, there is no change to what was reported in the Notes to the Results for the quarter ended June 30, 2008.
- In accordance with Clause 41 of the Listing Agreement with the Stock Exchanges, the Company's statutory auditors have conducted a 'Limited Review' of the financial results for the quarter ended September 30, 2008.
- The Board of Directors had declared an Interim Dividend of Rs. 3.50 per equity share of Rs 10 for the year ending December 31, 2008. The dividend (including the Dividend Distribution Tax) amounted to Rs. 94 million. The said dividend was paid on August 12, 2008 through Electronic Clearing Service /Dividend Warrants.
- Information on investor complaints is furnished below:

Pending as on July 1, 2008	Received during the quarter	Disposed of during the quarter	Pending as on September 30, 2008
Nil	7	7	Nil

- The figures for the previous periods have been re-grouped, wherever necessary.

AVENTIS PHARMA LIMITED
DR. SHAILESH AYYANGAR
MANAGING DIRECTOR